Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005087 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel, Cisplatin, and Filgrastim Combined With Radiation Therapy in Treating Patients With Locally Recurrent Head and Neck Cancer
A Phase 2 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
NCT00005087 is a Phase 2 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 105 participants.
The verdict
NCT00005087, a Phase 2 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase II trial to study the effectiveness of paclitaxel, cisplatin, and filgrastim combined with radiation therapy in treating patients who have locally recurrent head and neck cancer and have received previous treatment with radiation therapy.
Interventions
- DRUG cisplatin
- DRUG paclitaxel
- PROCEDURE conventional surgery
- RADIATION radiation therapy
- BIOLOGICAL filgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2000-03 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005087
The ClinicalTrials.gov registry entry for NCT00005087 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00005087 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005087 about?
NCT00005087 is a clinical study titled "Paclitaxel, Cisplatin, and Filgrastim Combined With Radiation Therapy in Treating Patients With Locally Recurrent Head and Neck Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from th...
What is the current status of trial NCT00005087?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2000-03. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00005087?
The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), conventional surgery (PROCEDURE), radiation therapy (RADIATION), filgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005087?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.